Novel Arylimidamides for Treatment of Visceral Leishmaniasis
Open Access
- 1 June 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (6), 2507-2516
- https://doi.org/10.1128/aac.00250-10
Abstract
Arylimidamides (AIAs) represent a new class of molecules that exhibit potent antileishmanial activity (50% inhibitory concentration [IC 50 ], Leishmania donovani axenic amastigotes and intracellular Leishmania , the causative agent for human visceral leishmaniasis (VL). A systematic lead discovery program was employed to characterize in vitro and in vivo antileishmanial activities, pharmacokinetics, mutagenicities, and toxicities of two novel AIAs, DB745 and DB766. They were exceptionally active (IC 50 ≤ 0.12 μM) against intracellular L. donovani , Leishmania amazonensis , and Leishmania major and did not exhibit mutagenicity in an Ames screen. DB745 and DB766, given orally, produced a dose-dependent inhibition of liver parasitemia in two efficacy models, L. donovani -infected mice and hamsters. Most notably, DB766 (100 mg/kg of body weight/day for 5 days) reduced liver parasitemia in mice and hamsters by 71% and 89%, respectively. Marked reduction of parasitemia in the spleen (79%) and bone marrow (92%) of hamsters was also observed. Furthermore, these compounds distributed to target tissues (liver and spleen) and had a moderate oral bioavailability (up to 25%), a large volume of distribution, and an elimination half-life ranging from 1 to 2 days in mice. In a repeat-dose toxicity study of mice, there was no indication of liver or kidney toxicity for DB766 from serum chemistries, although mild hepatic cell eosinophilia, hypertrophy, and fatty changes were noted. These results demonstrated that arylimidamides are a promising class of molecules that possess good antileishmanial activity and desirable pharmacokinetics and should be considered for further preclinical development as an oral treatment for VL.Keywords
This publication has 34 references indexed in Scilit:
- In Vitro Susceptibility of Field Isolates of Leishmania donovani to Miltefosine and Amphotericin B: Correlation with Sodium Antimony Gluconate Susceptibility and Implications for Treatment in Areas of EndemicityAntimicrobial Agents and Chemotherapy, 2009
- Inhibition by Dications of In Vitro Growth of Leishmania major and Leishmania tropica: Causative Agents of Old World Cutaneous LeishmaniasisJournal of Parasitology, 2008
- Inhibition by Dications of In Vitro Growth of Leishmania major and Leishmania tropica: Causative Agents of Old World Cutaneous LeishmaniasisJournal of Parasitology, 2008
- Cellular Effects of Reversed Amidines on Trypanosoma cruziAntimicrobial Agents and Chemotherapy, 2007
- Diphenyl Furans and Aza Analogs: Effects of Structural Modification on In Vitro Activity, DNA Binding, and Accumulation and Distribution in TrypanosomesAntimicrobial Agents and Chemotherapy, 2007
- CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime]Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2006
- The activity of diguanidino and ‘reversed’ diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovaniBioorganic & Medicinal Chemistry Letters, 2003
- Physicochemical Characteristics of Pentamidine-Loaded Polymethacrylate Nanoparticles: Implication in the Intracellular Drug Release inLeishmania MajorInfected MiceJournal of Drug Targeting, 1998
- Methods for detecting carcinogens and mutagens with the salmonella/mammalian-microsome mutagenicity testMutation Research/Environmental Mutagenesis and Related Subjects, 1975
- An Eight‐day Method for Screening Compounds against Leishmania donovani in the Golden Hamster*The Journal of Protozoology, 1958